References
- 1. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J. 2009;73:1893-1900.
- 2. Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, et al. Anemia is an independent predictor of long-term adverse outcomes in patients hospitalized with heart failure in Japan. A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J. 2009;73:1901-1908.
- 3. Suzuki S, Yoshihisa A, Yamaki T, et al. Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide. J Clin Pharmacol. 2013;53:1277-1285. doi: 10.1002/jcph.197.10.1002/jcph.197
- 4. Ambrosy AP, Pang PS, Khan S, et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J. 2013;34:835-843. doi: 10.1093/eurheartj/ehs444.10.1093/eurheartj/ehs444
- 5. Kinugawa K, Sato N, Inomata T, Shimakawa T, Iwatake N, Mizuguchi K. Efficacy and safety of tolvaptan in heart failure patients with volume overload. Circ J. 2014;78:844-852.
- 6. Suzuki S, Yoshihisa A, Yamaki T, et al. Long-term effects and prognosis in acute heart failure treated with tolvaptan: the AVCMA trial. Biomed Res Int. 2014;2014:704289. doi: 10.1155/2014/704289.
- 7. Kinugawa K, Inomata T, Sato N, et al. Effectiveness and adverse events of tolvaptan in octogenarians with heart failure. Interim analyses of Samsca Post-Marketing Surveillance In Heart faiLurE (SMILE study). Int Heart J. 2015;56:137-143. doi: 10.1536/ihj.14-332.10.1536/ihj.14-332
- 8. Kimura K, Momose T, Hasegawa T, et al. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. J Cardiol. 2016;67:399-405. doi: 10.1016/j.jjcc.2015.09.020.
- 9. Ono Y, Takamatsu H, Inoue M, et al. Clinical effect of long-term administration of tolvaptan in patients with heart failure and chronic kidney disease. Drug Discov Ther. 2018;12:154-160. doi: 10.5582/ddt.2018.01007.10.5582/ddt.2018.01007
- 10. Felker GM, Mentz RJ, Cole RT, et al. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69:1399-1406. doi: 10.1016/j.jacc.2016.09.004.
- 11. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441-1446. doi: 10.1056/NEJM197112232852601.10.1056/NEJM197112232852601
- 12. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Kardiol Pol. 2016;74:1037-1147. doi: 10.5603/KP.2016.0141.10.5603/KP.2016.0141
- 13. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61-67.
- 14. Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. Am J Cardiol. 2000;85:1110-1113.
- 15. Inomata T, Ikeda Y, Kida K, et al. Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment — results from the K-STAR study. Circ J. 2017;82:159-167. doi: 10.1253/circj.CJ-17-0179.10.1253/circj.CJ-17-0179
- 16. Matsue Y, Suzuki M, Torii S, et al. Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction. Int J Cardiol. 2016;221:188-193. doi: 10.1016/j.ijcard.2016.07.063.10.1016/j.ijcard.2016.07.063
- 17. Matsue Y, Ter Maaten JM, Suzuki M, et al. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. Clin Res Cardiol. 2017;106:802-812. doi: 10.1007/s00392-017-1122-1.10.1007/s00392-017-1122-1
- 18. Uemura Y, Shibata R, Takemoto K, et al. Safety and efficacy of long-term use of tolvaptan in patients with heart failure and chronic kidney disease. Circ J. 2017;81:1736-1738. doi: 10.1253/circj.CJ-17-055.10.1253/circj.CJ-17-055
- 19. Nakano Y, Mizuno T, Niwa T, et al. Impact of continuous administration of tolvaptan on preventing medium-term worsening renal function and long-term adverse events in heart failure patients with chronic kidney disease. Int Heart J. 2018;59:105-111. doi: 10.1536/ihj.16-625.10.1536/ihj.16-625
- 20. Kortebein P, Ferrando A, Lombeida J, Wolfe R, Evans WJ. Effect of 10 days of bed rest on skeletal muscle in healthy older adults. JAMA. 2007;297:1772-1774. doi: 10.1001/jama.297.16.1772-b.
- 21. Uemura Y, Shibata R, Takemoto K, et al. Prognostic impact of the preservation of activities of daily living on post-discharge outcomes in patients with acute heart failure. Circ J. 2018;82:2793-2799. doi: 10.1253/circj.CJ-18-0279.10.1253/circj.CJ-18-0279
- 22. Ueda K, Kasao M, Shimamura M, et al. Impact of oral treatment on physical function in older patients hospitalized for heart failure: a randomized clinical trial. PLoS One. 2016;11:e0167933. doi: 10.1371/journal.pone.0167933.
- 23. Imamura T, Kinugawa K. Tolvaptan improves the long-term prognosis in patients with congestive heart failure with preserved ejection fraction as well as in those with reduced ejection fraction. Int Heart J. 2016;57:600-606. doi: 10.1536/ihj.16-023.10.1536/ihj.16-023
- 24. Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000;140:840-847. doi: 10.1067/mhj.2000.110933.10.1067/mhj.2000.110933
- 25. Lala A, McNulty SE, Mentz RJ, et al. Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). Circ Heart Fail. 2015;8:741-748. doi: 10.1161/CIRCHEARTFAILURE.114.001957.